Intelligence Β· Patent portfolio
Vertex Pharmaceuticals (Australia) Patents
Full USPTO pharma patent portfolio for Vertex Pharmaceuticals (Australia) β grant dates, expiration, and drug cross-links.
- Patents
- 991
- Expiring β€24m
- 63
Quick answer
Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months β use filters for patent-cliff planning.
-
US 6420522
Inhibitors of interleukin-1&bgr; converting enzyme
expired -
US 6407080
N-(pyrimidinyl)-aspartic acid analogs as interleukin-1&bgr; converting enzyme inhibitors
expired -
US 6395763
Prodrugs of carbamate inhibitors of IMPDH
expired -
US 6392046
Sulfonamide inhibitors of aspartyl protease
expired -
US 6372778
Sulfonamide inhibitors of aspartyl protease
expired -
US 6350741
Inhibitors of interleukin-1&bgr; converting enzyme
expired -
US 6344465
Inhibitors of IMPDH enzyme
expired -
US 6329365
Inhibitors of interleukin-1.beta. converting enzyme
expired -
US 6326387
Methods and compositions for stimulating neurite growth
expired -
US 6319946
Inhibitors of aspartyl protease
expired -
US 6284779
Heteroaromatic compounds
expired -
US 6284778
Methods and compositions for stimulating neurite growth
expired -
US 6268384
Compounds possessing neuronal activity
expired -
US 6265380
Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
expired -
US 6258948
Inhibitors of Interleukin-1.beta. converting enzyme
expired -
US 6225350
Butyrate prodrugs derived from lactic acid
expired -
US 6204261
Inhibitors of interleukin-1.beta. Converting enzyme inhibitors
expired -
US 6172086
Methods and compositions for stimulating neurite growth
expired -
US 6162800
N-(pyrimidinyl)-aspartic acid analogs as interleukin-1.beta. converting enzyme inhibitors
expired -
US 6162790
Inhibitors of interleukin-1.beta. converting enzyme
expired -
US 6147080
Inhibitors of p38
expired -
US 6136787
Interleukin 1.beta. protease and interleukin 1.beta. protease inhibitors
expired -
US 6128582
Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
expired -
US 6127372
Sulfonamide inhibitors of aspartyl protease
expired -
US 6124328
Methods and compositions for stimulating neurite growth
expired -
US 6121266
Pyridazines as interleukin-1.beta. converting enzyme inhibitors
expired -
US 6103711
Inhibitors of interleukin-1.beta. converting enzyme
expired -
US 6054472
Inhibitors of IMPDH enzyme
expired -
US 6037370
Methods and compositions for stimulating neurite growth
expired -
US 6025147
Inhibitors of interleukin-1 .beta. converting enzyme
expired -
US 6011001
Method of protein therapy by orally administering crosslinked protein crystals
expired
Frequently asked questions
How many patents does Vertex Pharmaceuticals (Australia) have?
991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vertex Pharmaceuticals (Australia) patents expire?
63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory